Efficacy and Safety of Bevacizumab Plus Oxaliplatin- or Irinotecan-Based Doublet Backbone Chemotherapy as the First-Line Treatment of Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis

Tianshu Ren, Shu Wang, Zexu Shen, Chang Xu, Yingshi Zhang, Fuhai Hui, Xingshun Qi and Qingchun Zhao ()
Additional contact information
Tianshu Ren: Shenyang Pharmaceutical University
Shu Wang: Shenyang Pharmaceutical University
Zexu Shen: Shenyang Pharmaceutical University
Chang Xu: Shenyang Pharmaceutical University
Yingshi Zhang: Shenyang Pharmaceutical University
Fuhai Hui: Shenyang Pharmaceutical University
Xingshun Qi: General Hospital of Northern Theater Command
Qingchun Zhao: Shenyang Pharmaceutical University

Drug Safety, 2021, vol. 44, issue 1, No 4, 29-40

Abstract: Abstract Introduction and Objective Guidelines recommend combined doublet backbone chemotherapy based on 5-fluorouracil and oxaliplatin (OX) or irinotecan (IR) as the first-line treatment options for metastatic colorectal cancer. However, it is still unknown which is better when combined with bevacizumab (BEV). This systematic review and meta-analysis were performed to compare BEV-IR with BEV-OX regimens in terms of efficacy and safety. Methods We searched studies from databases including MEDLINE, EMBASE, CENTRAL, and conference papers. The outcomes were overall response rate, overall survival, progression-free survival, and the incidence of the most common adverse events. The dichotomous data were reported as the risk ratio (RR) and the survival outcomes were extracted as the hazard ratio with 95% confidence interval (CI). Results Eleven studies including 5632 patients were identified. No difference was found in overall survival or overall response rate between BEV-IR and BEV-OX regimens. The pooled progression-free survival was significantly longer in the BEV-IR group than the BEV-OX group (hazard ratio = 0.92, 95% CI 0.87–0.98, p = 0.08). Compared with the BEV-OX group, the BEV-IR group was related to a higher risk of bleeding events (RR = 0.80, 95% CI 0.64–0.98, p = 0.03), venous thromboembolism (RR = 0.60, 95% CI 0.46–0.79, p = 0.0002), and diarrhea (RR = 0.71, 95% CI 0.62–0.80, p

Date: 2021
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-020-00997-2 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:44:y:2021:i:1:d:10.1007_s40264-020-00997-2

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-020-00997-2

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().